QuantiWise tracks FDA-approved drugs through the Canadian regulatory pipeline — giving pharma, HEOR, and market access teams the intelligence they need for feasibility planning, reimbursement strategy, and program design.
Track every FDA-approved drug from US approval through Health Canada's NDS, NOC, and market launch — in one filterable dashboard.
Understand where drugs sit in the Canadian pipeline for feasibility planning, reimbursement forecasting, and study design timing.
Curated analysis of Canadian healthcare systems, drug pricing, HTA processes, and the forces shaping market access decisions.
I'm Dr. Richa Bagga — and this is a passion project, plain and simple. I kept running into the same gap: where does a drug actually stand in Canada after FDA approval? The answer was always scattered across databases, press releases, and memory.
So I started building this myself. QuantiWise is very much a work in progress — the data will grow, the features will evolve, and things may be rough around the edges. But the core idea is real, and I'm building it in the open.
If you find it useful, or have ideas on what would make it better — I'd genuinely love to hear from you. 👇
The US and Canada share the longest international border — but their pharmaceutical markets operate in completely different ways. Approval speed alone does not guarantee patients get treatment faster.
Homes are becoming the new clinics. From wearables to ambient sensors, the most important health decisions are happening outside hospital walls. Clinics must rethink their operational model.
Scaling Health-at-Home is not just about technology or staffing — it's about reconfiguring how care flows across people, systems, and data.
LillyPod's strategic intent goes beyond scale — it's about escaping pharma's boom-and-bust cycle through AI-driven R&D and decades of research data.
As hospitals face capacity strain and Canada's population ages, home health is becoming the pressure valve of the system — but integration isn't keeping pace.
IMD's 2025 Future Readiness Indicator shows blockbusters alone won't cut it. Platform thinking, AI integration, and ecosystem leverage separate the leaders.
30 FDA-approved drugs. Canadian regulatory status. Pipeline progress. All in one filterable, exportable view — free to use.